Manchester Capital Management LLC Buys 110 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Manchester Capital Management LLC increased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 86.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 237 shares of the biotechnology company’s stock after purchasing an additional 110 shares during the quarter. Manchester Capital Management LLC’s holdings in Sarepta Therapeutics were worth $29,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of SRPT. Simplify Asset Management Inc. grew its stake in Sarepta Therapeutics by 84.6% in the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after buying an additional 88,474 shares in the last quarter. Geode Capital Management LLC grew its stake in Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after buying an additional 44,306 shares in the last quarter. Summit Partners Public Asset Management LLC grew its stake in Sarepta Therapeutics by 547.9% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock valued at $17,250,000 after buying an additional 116,800 shares in the last quarter. Larson Financial Group LLC grew its stake in Sarepta Therapeutics by 1,649.8% in the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock valued at $1,093,000 after buying an additional 8,249 shares in the last quarter. Finally, abrdn plc grew its stake in Sarepta Therapeutics by 30.7% in the 3rd quarter. abrdn plc now owns 431,098 shares of the biotechnology company’s stock valued at $53,935,000 after buying an additional 101,253 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on SRPT shares. Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. HC Wainwright restated a “sell” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday. Robert W. Baird reduced their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Jefferies Financial Group started coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 price target for the company. Finally, Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $176.77.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $107.95 on Monday. Sarepta Therapeutics, Inc. has a 1 year low of $102.15 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company’s 50-day moving average is $119.42 and its 200 day moving average is $124.60. The stock has a market capitalization of $10.31 billion, a P/E ratio of 86.36 and a beta of 0.75.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.